Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

Ioannis Boukovinas, Chara Papadaki, Pedro Mendez et al. · 2008

Read Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients by Ioannis Boukovinas, Chara Papadaki, Pedro Mendez et al. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0003695.txt.

Description

Ioannis Boukovinas, Chara Papadaki, Pedro Mendez, and colleagues published this lung cancer study in PLOS ONE in 2008. Patients with advanced non-small-cell lung cancer often get gemcitabine plus docetaxel as first treatment. High levels of some tumor genes have been tied to drug resistance or sensitivity.

The team measured BRCA1, RRM1, and RRM2 message levels in tumors and compared them with how patients fared. Earlier work linked high RRM1 and RRM2 to gemcitabine resistance. The three-gene readout offers a step toward matching chemotherapy to the profile of each patient's tumor.

Catalog record

CREATORIoannis Boukovinas, Chara Papadaki, Pedro Mendez et al.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003695

Browse the full library · About the Tower of Babel